Q1 2025 Devyser Diagnostics AB Earnings Call Transcript
Key Points
- Devyser Diagnostics AB (FRA:OL0) reported its second strongest revenue quarter in company history, with SEK 55 million, marking an 8% growth compared to Q1 last year.
- The company achieved a gross margin of 83%, indicating strong profitability potential.
- Devyser is focusing on two key customer segments: clinical genetic labs and transplantation laboratories, which are expected to address unmet diagnostic needs.
- The company is advancing its transplantation diagnostics strategy by decentralizing tests, which could lead to faster turnaround times and lower costs.
- Devyser has initiated an FDA project for its cfDNA product, with promising early adoption by US customers even before FDA approval.
- The EBIT was negative at minus SEK 21 million, impacted by SEK 8 million in reorganization costs and SEK 6 million in FX headwinds.
- Revenue growth of 7.9% was lower than the previous quarter, indicating potential volatility in quarterly performance.
- The EMEA region, while the largest market, showed less growth than usual this quarter.
- The company faced challenges with a strong Swedish Krona, leading to a SEK 6 million negative FX impact.
- There are ongoing restructuring costs that will continue to impact financials into Q2.
Good day and welcome to the Devyser Q1 2025 earnings call. I'm Fredrik Dahl, I'm the acting CEO of Devyser and would like to thank you everyone for joining our call today.
On the call today, we have, in addition to myself, also our CFO, Sabina Berlin and our Chief Commercial Officer, Theis Kipling.
I will start with a short summary of our quarterly results and then recap our updated strategy and present some highlights from the team before handing over to Sabina for more detailed review of our financial results in Q1 2025, and then to Theis for an update on our commercial activities.
We had another solid quarter based on revenue, the second strongest quarter in the history of the company. The revenue was SEK 55 million, representing a growth of 8% comparing, compared to Q1 last year. Gross margins were 83% and EBIT minus SEK 21 million.
Including SEK 8 million in one-offs related to reorg and another SEK 6 million in FX headwinds. Our cash position was SEK 114 million.
As mentioned on the previous call,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
